Risperidone on apomorphine-induced stereotyped behavior and auditory sensory gating in rhesus monkeys. 2022

Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
Platform Technology Research Unit, Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, Japan.

The ameliorating effect of risperidone on apomorphine-induced stereotyped behavior and inhibition of auditory sensory gating was investigated using rhesus monkeys. The total duration of the stereotyped behavior observed in the control group was 43.7 ± 23.0 s (n = 3) between 10 and 25 min after vehicle administration, whereas the duration in the apomorphine-treated (0.1 or 0.15 mg/kg i.m., n = 3) group was observed to be significantly prolonged to 413.0 ± 150.6 s. Administration of 0.01, 0.03, 0.1 mg/kg of risperidone 60 min before apomorphine, significantly reduced the duration of this apomorphine-induced stereotyped behavior to 327 ± 104.9 s (n = 3), 8.3 ± 4.2 s (n = 3), and 0.0 ± × 0.0 s (n = 3, t-test: p < 0.05), respectively. Next, the auditory sensory gating test/conditioning (T/C) ratio was used as a bio-marker. The T/C ratio was 0.598 ± 0.0802 in the vehicle-administered control group (n = 4) and was significantly increased to 2.098 ± 0.254 (n = 4) by apomorphine (0.15 mg/kg, i.m.). Administering of risperidone (0.1 mg/kg, s.c.) 30 min before apomorphine treatment significantly restricted the T/C ratio to 0.571 ± 0.0886 (n = 4), compared to the T/C ratio in the vehicle-administered control group. The above results demonstrate, not only behaviorally but also electrophysiologically, the ameliorating effect of risperidone on the induction of schizophrenia-like symptoms by apomorphine in non-human primates.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D013239 Stereotyped Behavior Relatively invariant mode of behavior elicited or determined by a particular situation; may be verbal, postural, or expressive. Behavior, Stereotyped,Behaviors, Stereotyped,Stereotyped Behaviors
D055139 Sensory Gating The ability of the BRAIN to suppress neuronal responses to external sensory inputs, such as auditory and visual stimuli. Sensory filtering (or gating) allows humans to block out irrelevant, meaningless, or redundant stimuli. Acoustic Startle Gating,Auditory Sensory Gating,Sensorimotor Gating,Sensory Filtering,Startle Gating,Filtering, Sensory,Gating, Acoustic Startle,Gating, Auditory Sensory,Gating, Sensorimotor,Gating, Sensory,Gating, Startle
D018967 Risperidone A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. R-64,766,R-64766,Risperdal Consta,Risperidal,Consta, Risperdal,R 64,766,R 64766,R64,766,R64766

Related Publications

Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
April 1975, European journal of pharmacology,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
February 1987, Brain research,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
April 1974, The Journal of pharmacy and pharmacology,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
November 1981, Pharmacology, biochemistry, and behavior,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
April 2005, Neuroreport,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
March 1990, Pharmacology, biochemistry, and behavior,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
May 1997, Progress in neuro-psychopharmacology & biological psychiatry,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
April 1974, Life sciences,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
January 1987, General pharmacology,
Yoshihiro Iwamura, and Tomokazu Nakako, and Atsushi Matsumoto, and Yuji Ogi, and Masataka Yamaguchi, and Atsushi Kobayashi, and Kenji Matsumoto, and Yasunori Katsura, and Kazuhito Ikeda
January 1978, Communications in psychopharmacology,
Copied contents to your clipboard!